Work

Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors

Year: 2004

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-0980-3

Authors: David P. Ryan, Joseph P. Eder, Thomas Puchlaski, Michael V. Seiden, Thomas J. Lynch, Charles S. Fuchs, Philip C. Amrein, Darrell Sonnichsen, Jeffrey G. Supko, Jeffrey W. Clark

Institutions: Massachusetts General Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Bristol-Myers Squibb (United States)

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2104811481

FWCI: 2.077

Cites: 24

Cited by: 33

Related to: 10